Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections

Bone Marrow Transplantation

Volumn 38, Issue 5, 2006, Pages 327-337

  Safdar, A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antifungal therapy; Hematopoietic stem cell transplant; Immune enhancement; Systematic fungal infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CASPOFUNGIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DENDRITIC CELL VACCINE; ECHINOCANDIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MELPHALAN; MICAFUNGIN; PENTRAXIN; POSACONAZOLE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GAMMA INTERFERON 1B; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ASPERGILLOSIS; ASPERGILLUS; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DENDRITIC CELL; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; ENZYME IMMUNOASSAY; FUNGUS CULTURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GRANULOCYTE TRANSFUSION; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HOST SUSCEPTIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; INNATE IMMUNITY; INTERMETHOD COMPARISON; MUCORMYCOSIS; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ANTIFUNGAL AGENTS; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY; IMMUNITY, NATURAL; IMMUNOENZYME TECHNIQUES; MYCOSES; PREDICTIVE VALUE OF TESTS;

EID: 33747352548     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705439     Document Type: Review

References (95)

1. Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 2001; 17: 531-570.
2. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
3. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
4. Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kohkola P et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-808.
5. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant 2002; 8: 512-520.
6. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V et al. Late onset invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-19.
7. Safdar A, Papadopoulous EB, Armstrong D. Listeriosis in recipients of allogeneic blood and marrow transplantation: Thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. Bone Marrow Transplant 2002; 29: 913-916.
8. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: No adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28: 873-878.
9. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplnatation patients: A randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112: 369-379.
10. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 2003; 138: 705-713.
11. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changing in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
12. Groll AH, Walsh TJ. Uncommon opportunistic fungi: New nosocomial threats. Clin Microbiol Infect 2001; 7 (Suppl 2): 8-24.
13. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
14. Safdar A, Singhal S, Mehta J. clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001). Cancer 2004; 100: 2456-2461.
15. Lionakis MS, Kontoyiannis DP. The significance of isolation of saprophytic moulds from the lower respiratory tract in patients with cancer. How do the European Organization for Research and Treatment of Cancer/Mycosis Study Group criteria apply? Cancer 2004; 100: 165-172.
16. Horger M, Hebart H, Einsele H, Lengerke C, Claussen CD, Vonthein R et al. Initial CT manifestation of invasive pulmonary aspergillosis in 45 non-HIV immunocomprmised patients: Association with patient outcome. Eur J Radiol 2005; 55: 437-444.
17. Hoger M, Einselle H, Schumacher U, Wehrman M, Hebart H, Lengerke C et al. Invasive pulmonary aspergillosis: Frequency and meaning of the 'hypodense sign' on unenhanced CT. Br J Radiol 2005; 78: 697-703.
18. Franquet T, Muller NL, Gimenez A, Martinez S, Madrid M, Domingo P. Infectious pulmonary nodules in immunocompromised patients: Usefulness of computed tomography in predicting their etiology. J Comput Assist Tomogr 2003; 27: 461-468.
19. Kim MJ, Lee KS, Kim J, Jung KJ, Lee HG, Kim TS. Crescent sign in invasive pulmonary aspergillosis: Frequency and related CT and clinical factors. J Comput Assist Tomogr 2001; 25: 305-310.
20. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
21. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
22. Musher B, Fredricks D, Leisening W, Balajee SA, Smith C, Marr KA. Aspergillus galactomanna enzyme immunoassays and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517-5522.
23. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassays. Clin Infect Dis 2005; 40: 1762-1769.
24. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-486.
25. Florent M, Katsahian S, Vekhoff A, Levy V, Rio B, Marie JP et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematologic malignancies. J Infect Dis 2006; 193: 741-747.
26. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systemic review of the literature. Clin Infect Dis 2001; 32: 358-366.
27. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
28. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-1032.
29. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-299.
30. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy or invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
31. Safdar A, Rodriguez G, Rolston KV, Kantarjian H, Bodey G, Champlin R et al. Efficacy of high-dose (100mg daily) caspofungin (HD-CASP) combination antifungal therapy in cancer patients with invasive fungal infections (IFIs): Case-control observational analysis during 2002-2004. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy 2005, December 16-19, 2005, Washington, DC (abstr. M-955).
32. Maertens, J, Glasmacher A, Herbrecht R, Aoun M, Thiebaut A, Cordonnier C et al. Multicenter, noncomparative study of caspofungin (CAS) combination with other antifungals in adults with invasive Aspergillus (IA) refractory® or intolerant (I) to prior therapy (Rx): Final data. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, 2005, Washington, DC (abstr. M-954).
33. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-133.
34. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summery of 91 cases. Clin Infect Dis 2006; 42: E61-e65.
35. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-1403.
36. Balloy V, Si-Tahar M, Takeuchi O, Philippe B, Nahori MA, Tanguy M et al. Involvement of Toll-like receptor 2 in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 5420-5425.
37. Wang JE, Warris A, Ellingsen EA, Jorgensen PF, Flo TH, Espevi KT et al. Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun 2001; 69: 2402-2406.
38. Netea M, Warris A, Van der Meer JWM, Fenton MJ, Verver-Janssen TJ, Jacobs LE et al. Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 2003; 188: 320-326.
39. Rolides E, Dimitriadou-Georgiadou A, Sein T, Kadiltsoglou I, Walsh TJ. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immunol 1998; 66: 5999-6003.
40. Mehrad B, Strieter RM, Standiford TJ. Role of TNF-α in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162: 1633-1640.
41. Mehrad B, Strieter RM, Moore TA, Tsai WC, Lira SA, Standiford TJ. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J Immunol 1999; 163: 6086-6094.
42. Traynor TR, Herring AC, Dorf ME, Kuziel WA, Toews GB, Huffnagle GB. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J Immunol 2002; 168: 4659-4666.
43. Carpenter KJ, Hogaboam CM. Immunosuppressive effects of CCL17 on pulmonary antifungal responses during pulmonary invasive aspergillosis. Infect Immun 2005; 73: 7198-7207.
44. Cenci E, Mencacci A, Del Sero G, Bacci A, Montagnoli C, d'Ostiani CF et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I response. J Infect Dis 1999; 180: 1957-1968.
45. Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100: 4521-4528.
46. Mencacci A, Perruccio K, Bacci A, Cenci E, Benedetti R, Martelli MF et al. Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood 2001; 97: 1483-1490.
47. Rivera A, Van Epps HL, Hohl TM, Rizzuto G, Pamer EG. Distinct CD4+-T-cell responses to live and heat-inactivated Aspergillus fumigatus conidia. Infect Immun 2005; 73: 7170-7179.
48. Gersuk GM, Underhill DM, Zhu L, Marr KA. Dectin-1 and TLR permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol 2006; 176: 3717-3724.
49. Hohl TM, Van Epps HL, Rivera A, Morgan LA, Chen PL, Feldmesser M et al. Aspergillus fumigatus triggers inflammatory response by stage-specific b-glucan display. PLoS Pathog 2005; 1: E30.
50. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828-1838.
51. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitaive relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
52. Stanzani M, Orciuolo E, Lewis R, Kontoyiannis DP, Martins SL, St John LS et al. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood 2005; 105: 2258-2265.
53. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
54. Freireich EJ, Morse EE, Bronson W, Carbone PP. Transfusion of granulocytes from donors with chronic myelocytic leukemia to leukopenic recipients. Proc IXth Congr Int Soc Hematol 1962; 1: 549-557.
55. Freireich EJ, Judson G, Levin RH. Separation and collection of leukocytes. Cancer Res 1965; 25: 1516-1520.
56. Freireich EJ. White cell transfusions born again. Leuk Lymph 1993; 11 (Suppl 2): 161-165.
57. Hubel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: A comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002; 42: 1414-1421.
58. Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005; 84: 734-741.
59. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: A meta-analysis. J Clin Apher 1997; 12: 74-81.
60. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia. Retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101: 2859-2865.
61. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
62. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immunol 1993; 61: 1185-1193.
63. Schuening FG, Nemunaitis J, Appelbaum FR, Storb R. Hematopoietic growth factors after allogeneic marrow transplantation in animal studies and clinical trials. Bone Marrow Transplant 1994; 14 (Suppl 4): 74-77.
64. Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II et al. The safety of interferon-γ-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005; 103: 731-739.
65. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ et al. Recombinant interferon γ1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006; 106: 2664-2671.
66. Bittencourt H, Rocha V, Filion A, Ionescu I, Herr AL, Garnier F et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant 2005; 36: 431-435.
67. Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: Current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon gamma. J Infect Dis 2002; 185: 1490-1501.
68. van Eijk M, van Roomen CPAA, Renkema GH, Bussink AP, Andrews L, Blommaart EF et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Intern Immunol 2005; 17: 1505-1512.
69. Choi JH, Brummer E, Kang YK, Jones PP, Stevens DA. Inhibitor kappaB and nuclear factor kappaB in granulocytemacrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. J Infect Dis 2006; 193: 1023-1028.
70. Brummer E, Kamberi M, Stevens DA. Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vitro of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis 2003; 187: 705-709.
71. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420: 182-186.
72. Gaziano R, Bozza S, Bellocchio S, Perruccio K, Montagnoli C, Pitzurra L et al. Anti-Aspergillus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother 2004; 48: 4414-4421.
73. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397-4406.
74. Beck O, Topp MS, Koehl U, Poilides E, Simitsopoulou M, Hanisch M et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 2006; 107: 2562-2569.
75. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, Burchielli E et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102: 3807-3814.
76. Bozza S, Gaziano R, Spreca A, Bacci A, Montagnoli C, di Francesso P et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J immunol 2002; 168: 1362-1371.
77. Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, Morgan C et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: A 1-year retrospective study of consecutive patients at Freach transplantation centers. Clin Infect Dis 2006; 42: 955-963.
78. Maertens J, Verhaegen J, Lagrou K, Eldere JV, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnositic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001; 97: 1604-1610.
79. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogstenden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk fro invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448-457.
80. Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Vandenberghe P et al. Autopsy-controlled prospective evalaution of serial screening for circulating galactomnannan by sandwich enzyme-linked immunosorbant asay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-3228.
81. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis 2004; 190: 641-649.
82. Machetti M, Feasi M, Mordini N, Van Lint MT, Bacigalupo A, Latge JP et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998; 21: 917-921.
83. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119: 144-154.
84. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178-185.
85. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
86. Canals C, Martino R, Sureda A, Altes A, Briones J, Subira M et al. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34 + cell selection. Exp Hematol 2003; 31: 1039-1043.
87. Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Jakobsen BK, Sengelov H et al. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: Results, complications and admission requirements in a single institution. Br J Haematol 2004; 125: 225-231.
88. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144-151.
89. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-1814.
90. Kojima R, Kami M, Kanda Y, Kusumi E, Kishi Y, Tanaka Y et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 2005; 36: 667-674.
91. Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005; 36: 683-689.
92. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 2004; 104: 961-968.
93. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 2006; 20: 128-135.
94. Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transplant Infect Dis 2004; 6: 171-178.
95. Kogan TV, Jadoun J, Mittelman L, Hirschberg K, Osherov N. Involvement of secreted Aspergillus fumigatus proteases in disruption of the actin fiber cytoskeleton and loss of focal adhesion sites in infected A549 lung pneumocytes. J Infect Dis 2004; 189: 1965-1973.